These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 35414524)

  • 1.
    Bhardwaj N; Rohilla M; Trehan A; Bansal D; Kakkar N; Srinivasan R
    J Clin Pathol; 2023 Sep; 76(9):599-605. PubMed ID: 35414524
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ALK Gene Mutation and ALK Protein Expression in Advanced Neuroblastoma and the Potential Value in Risk Stratification in Fine-Needle Aspiration Biopsy Samples.
    Bhardwaj N; Rohilla M; Gautam U; Trehan A; Bansal D; Kakkar N; Srinivasan R
    Am J Clin Pathol; 2023 Apr; 159(4):407-415. PubMed ID: 36812383
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Histopathology (International Neuroblastoma Pathology Classification) and MYCN status in patients with peripheral neuroblastic tumors: a report from the Children's Cancer Group.
    Goto S; Umehara S; Gerbing RB; Stram DO; Brodeur GM; Seeger RC; Lukens JN; Matthay KK; Shimada H
    Cancer; 2001 Nov; 92(10):2699-708. PubMed ID: 11745206
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Age, Diagnostic Category, Tumor Grade, and Mitosis-Karyorrhexis Index Are Independently Prognostic in Neuroblastoma: An INRG Project.
    Sokol E; Desai AV; Applebaum MA; Valteau-Couanet D; Park JR; Pearson ADJ; Schleiermacher G; Irwin MS; Hogarty M; Naranjo A; Volchenboum S; Cohn SL; London WB
    J Clin Oncol; 2020 Jun; 38(17):1906-1918. PubMed ID: 32315273
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mitosis-Karyorrhexis Index evaluation by digital image visual analysis for application of International Neuroblastoma Pathology Classification in FNA biopsy.
    Bhardwaj N; Rohilla M; Trehan A; Bansal D; Kakkar N; Srinivasan R
    Cancer Cytopathol; 2022 Feb; 130(2):128-135. PubMed ID: 34633743
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytopathological spectrum of peripheral neuroblastic tumours in fine needle aspiration cytology and categorisation as per International Neuroblastoma Pathology Classification.
    Koshy A; Jain R; Srinivasan R; Bhatia P; Kakkar N; Rajwanshi A; Gupta N; Dey P; Trehan A; Bansal D
    Cytopathology; 2019 Nov; 30(6):634-643. PubMed ID: 31231909
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comprehensive evaluation of context dependence of the prognostic impact of MYCN amplification in neuroblastoma: A report from the International Neuroblastoma Risk Group (INRG) project.
    Campbell K; Shyr D; Bagatell R; Fischer M; Nakagawara A; Nieto AC; Brodeur GM; Matthay KK; London WB; DuBois SG
    Pediatr Blood Cancer; 2019 Aug; 66(8):e27819. PubMed ID: 31115156
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enlarged and prominent nucleoli may be indicative of MYCN amplification: a study of neuroblastoma (Schwannian stroma-poor), undifferentiated/poorly differentiated subtype with high mitosis-karyorrhexis index.
    Kobayashi C; Monforte-Munoz HL; Gerbing RB; Stram DO; Matthay KK; Lukens JN; Seeger RC; Shimada H
    Cancer; 2005 Jan; 103(1):174-80. PubMed ID: 15549714
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neuroblastoma: Application of International Neuroblastoma Pathology Classification on fine needle aspiration cytology smears.
    Rastogi K; Mahajan N; Khatri A; Khan NA
    Indian J Pathol Microbiol; 2022; 65(2):387-391. PubMed ID: 35435376
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Age-dependent prognostic effect by Mitosis-Karyorrhexis Index in neuroblastoma: a report from the Children's Oncology Group.
    Teshiba R; Kawano S; Wang LL; He L; Naranjo A; London WB; Seeger RC; Gastier-Foster JM; Look AT; Hogarty MD; Cohn SL; Maris JM; Park JR; Shimada H
    Pediatr Dev Pathol; 2014; 17(6):441-9. PubMed ID: 25207821
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Prognostic significance of MYCN amplification in children neuroblastic tumors].
    Niu H; Xu T; Wang F; Chen Z; Gao Q; Yi P; Xia J
    Zhonghua Bing Li Xue Za Zhi; 2015 Feb; 44(2):111-7. PubMed ID: 25916642
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MYCN RNA levels determined by quantitative in situ hybridization is better than MYCN gene dosages in predicting the prognosis of neuroblastoma patients.
    Chang HH; Tseng YF; Lu MY; Yang YL; Chou SW; Lin DT; Lin KH; Jou ST; Hsu WM; Jeng YM
    Mod Pathol; 2020 Apr; 33(4):531-540. PubMed ID: 31695155
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neuroblastomas with discordant genotype-phenotype relationships: report of four cases with MYCN amplification and favorable histology.
    Nakagawa A; Matsuoka K; Okita H; Iwafuchi H; Hori H; Kumagai M
    Pediatr Dev Pathol; 2011; 14(2):87-92. PubMed ID: 21288077
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Complete surgical resection improves outcome in INRG high-risk patients with localized neuroblastoma older than 18 months.
    Fischer J; Pohl A; Volland R; Hero B; Dübbers M; Cernaianu G; Berthold F; von Schweinitz D; Simon T
    BMC Cancer; 2017 Aug; 17(1):520. PubMed ID: 28778185
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Significance of MYCN amplification in international neuroblastoma staging system stage 1 and 2 neuroblastoma: a report from the International Neuroblastoma Risk Group database.
    Bagatell R; Beck-Popovic M; London WB; Zhang Y; Pearson AD; Matthay KK; Monclair T; Ambros PF; Cohn SL;
    J Clin Oncol; 2009 Jan; 27(3):365-70. PubMed ID: 19047282
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Significance of clinical and biologic features in Stage 3 neuroblastoma: a report from the International Neuroblastoma Risk Group project.
    Meany HJ; London WB; Ambros PF; Matthay KK; Monclair T; Simon T; Garaventa A; Berthold F; Nakagawara A; Cohn SL; Pearson AD; Park JR
    Pediatr Blood Cancer; 2014 Nov; 61(11):1932-9. PubMed ID: 25044743
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report.
    Cohn SL; Pearson AD; London WB; Monclair T; Ambros PF; Brodeur GM; Faldum A; Hero B; Iehara T; Machin D; Mosseri V; Simon T; Garaventa A; Castel V; Matthay KK;
    J Clin Oncol; 2009 Jan; 27(2):289-97. PubMed ID: 19047291
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Augmented expression of MYC and/or MYCN protein defines highly aggressive MYC-driven neuroblastoma: a Children's Oncology Group study.
    Wang LL; Teshiba R; Ikegaki N; Tang XX; Naranjo A; London WB; Hogarty MD; Gastier-Foster JM; Look AT; Park JR; Maris JM; Cohn SL; Seeger RC; Asgharzadeh S; Shimada H
    Br J Cancer; 2015 Jun; 113(1):57-63. PubMed ID: 26035700
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Survival of Patients With Neuroblastoma After Assignment to Reduced Therapy Because of the 12- to 18-Month Change in Age Cutoff in Children's Oncology Group Risk Stratification.
    Bender HG; Irwin MS; Hogarty MD; Castleberry R; Maris JM; Kao PC; Zhang FF; Naranjo A; Cohn SL; London WB
    J Clin Oncol; 2023 Jun; 41(17):3149-3159. PubMed ID: 37098238
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic value of the International Neuroblastoma Pathology Classification in Neuroblastoma (Schwannian stroma-poor) and comparison with other prognostic factors: a study of 182 cases from the Spanish Neuroblastoma Registry.
    Burgues O; Navarro S; Noguera R; Pellín A; Ruiz A; Castel V; Llombart-Bosch A
    Virchows Arch; 2006 Oct; 449(4):410-20. PubMed ID: 16941154
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.